Since tumor-derived HMGB-1 may inhibit anti-tumor T cell responses through the ligation of TIM-3 on T cells and the up-regulation of HLA-G on tumor cells, an inhibitor of HMGB-1 may be tested in combination with anti-HLA-G antibodies. Here, HMGB1 is linked to neoplasm.